Quarterly Outlook
Macro Outlook: The US rate cut cycle has begun
Peter Garnry
Chief Investment Strategist
Over the last seven days Saxo UK clients have been adding to investments in Nike, Broadcom, and GSK, all companies that provided key updates in the last couple of weeks.
Nike shares plunged 20% as quarterly revenue came in lower than estimates and their FY25 1H revenue outlook indicated only mid-single digit revenue growth as sales face several headwinds. The share price fall was the worst since the company’s 1980 stock debut and proved to be an enticing entry point for new investors.
- Exploring Nike through analyst insights
We have seen new positions being taken in Broadcom ahead of the schedule 10:1 stock split due on 15th July. The semiconductor company’s shares have increased 10% since the stock split was announced as it follows in the footsteps of Nvidia in making a split. Although stock splits are mathematically price neutral, they are often instigated because of strong share price performance and open the opportunity for smaller investment amounts post-split.
- Strong bullish indicators before Broadcom stock split
GSK fell the most since January after the US Advisory Committee on Immunisation practices delayed backing the use of GSK’s respiratory vaccine Arexvy in younger adults. The decision has the potential to hurt the uptake of the GSK treatment versus competitors. The shares have now given up nearly all their gains for 2024 and trade well below the average analyst target 1949p.
- CDC narrows age recommendation for RSV shots